ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2692

Individualized Strength, Mobility and Aerobic Rehabilitation Training in axial Spondyloarthritis (iSMART in axSpA)

Sophie De Mits1, Tine Willems2, Lieven Danneels2, Patrick Calders2, Gaëlle Varkas3, Filip Van den Bosch4, Dirk Elewaut5 and Philippe Carron6, 1Ghent University Hospital, Gent, Belgium, 2Ghent University, Gent, Belgium, 3Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 4Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, 6Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

Meeting: ACR Convergence 2025

Keywords: clinical trial, exercise, Muscle strength, Rehabilitation, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 29, 2025

Title: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Pathogenesis, Exercise, and Dietary Interventions (2687–2692)

Session Type: Abstract Session

Session Time: 12:45PM-1:00PM

Background/Purpose: AxSpA primarily affects the sacroiliac joints and spine, reducing trunk strength, mobility, and cardiorespiratory fitness. While exercise is a key treatment, few studies have examined combined trunk mobility and strength training with cardiorespiratory training. This prospective interventional study assessed the benefits of a combined and personalized exercise intervention based on baseline physical tests.

Methods: Participants with AxSpA completed a baseline maximal Cardiopulmonary Exercise Test (CPET) and trunk strength/mobility tests using David Back Concept (DBC) devices. Strength and mobility deficits were calculated as: (Reference − Patient value) × 100 / Reference. BASDAI, BASFI, BASMI, and chest expansion (CE) were registered pre- and post-intervention. The 8-week program consists of two weekly sessions of two 10-minute intervals of cardiorespiratory training at a set heart rate (HR), followed by DBC device exercises. Cardiorespiratory intensity was based on ventilatory threshold 1 (VT1) and monitored via a Polar HR device. Trunk training focused on mobility and resistance using each patient’s one-repetition-maximum and maximal range of motion at baseline. All sessions were supervised to ensure correct execution and safety. Post-intervention, CPET and DBC tests were repeated. Linear mixed models analyzed changes over time.

Results: Thirty axSpA patients (14M/16F, age 42±11.2 years; BASDAI 3.5±2.1, BASFI 2.8±2.2, BASMI 2.0±1.1, CE 4.5±2.0 cm) participated; 2 patients were lost to follow-up (1: flare, 2: personal reasons). Strength increased on average by 14.1% (p< 0.001), and mobility improved by 14.9% (p< 0.001) on average, with significant time and direction effects.(See Fig.1) Cardiorespiratory parameters improved significantly: oxygen pulse (p=0.004), ventilatory efficiency (p< 0.001), anaerobic threshold (p=0.002), and mechanical efficiency (p=0.021), but not efficiency slope (p=0.888). (See Table 1) BASDAI (2.9±2.2, p=0.021) and CE (5.0±2.1 cm, p=0.020) showed significant improvement, while BASMI (1.8±1.0, p=0.053) showed a borderline significant decrease and BASFI (2.4±2.1, p=0.092) did not differ significantly. (See Table 2)

Conclusion: A combined, individually tailored exercise program, dependent on baseline objectively measured physical parameters, significantly improved cardiorespiratory fitness, trunk strength, and mobility in AxSpA patients. These results support the role of individualized exercise interventions in enhancing patient outcomes and reducing functional limitations.

Supporting image 1Fig.1: Mean strength (A) and mobility (B) deficit before and after the training program for the different directions.

Supporting image 2Table 1: cardiorespiratory parameters before and after intervention

Supporting image 3Table 2: clinical parameters before and after intervention


Disclosures: S. De Mits: None; T. Willems: None; L. Danneels: None; P. Calders: None; G. Varkas: AbbVie, 2, 5, 6, Amgen, 2, 6, Celltrion, 2, 5, 6, EG, 5, Eli Lilly, 2, 6, Galapagos, 2, 5, 6, Janssen, 2, 6, MSD, 5, Novartis, 2, 6, Pfizer, 2, 5, 6, Takeda, 5, UCB, 2, 6; F. Van den Bosch: AbbVie, 2, 6, Alfasigma, 2, Amgen, 2, 6, Eli Lilly, 2, Galapagos, 2, Grey Wolf Therapeutics, 2, Janssen, 2, 6, Merck, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2, 6; D. Elewaut: AbbVie, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Novartis, 2, 6, UCB, 2, 6; P. Carron: AbbVie/Abbott, 2, 6, Alfasigma, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Johnson & Johnson, 2, 6, Novartis, 2, 6, UCB, 2, 6.

To cite this abstract in AMA style:

De Mits S, Willems T, Danneels L, Calders P, Varkas G, Van den Bosch F, Elewaut D, Carron P. Individualized Strength, Mobility and Aerobic Rehabilitation Training in axial Spondyloarthritis (iSMART in axSpA) [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/individualized-strength-mobility-and-aerobic-rehabilitation-training-in-axial-spondyloarthritis-ismart-in-axspa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/individualized-strength-mobility-and-aerobic-rehabilitation-training-in-axial-spondyloarthritis-ismart-in-axspa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology